T. Rowe Price Associates
ALLO icon

T. Rowe Price Associates’s Allogene Therapeutics ALLO Stock Holding History

T. Rowe Price Associates’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.65M Sell
4,639,283
-741,619
-14% -$1.63M ﹤0.01% 1341
2026
Q1 		$13.1M Buy
5,380,902
+2,171,627
+68% +$4.35M ﹤0.01% 1149
2025
Q4 		$4.4M Sell
3,209,275
-468,199
-13% -$618K ﹤0.01% 1430
2025
Q3 		$4.56M Sell
3,677,474
-353,398
-9% -$421K ﹤0.01% 1419
2025
Q2 		$4.56M Sell
4,030,872
-175,132
-4% -$233K ﹤0.01% 1299
2025
Q1 		$6.14M Sell
4,206,004
-279,568
-6% -$527K ﹤0.01% 1213
2024
Q4 		$9.55M Sell
4,485,572
-353,171
-7% -$871K ﹤0.01% 1166
2024
Q3 		$13.6M Sell
4,838,743
-951,799
-16% -$2.54M ﹤0.01% 1082
2024
Q2 		$13.5M Buy
5,790,542
+1,612,923
+39% +$4.76M ﹤0.01% 1052
2024
Q1 		$18.7M Buy
4,177,619
+1,806,147
+76% +$7.54M ﹤0.01% 989
2023
Q4 		$7.61M Sell
2,371,472
-35,875
-1% -$102K ﹤0.01% 1145
2023
Q3 		$7.63M Sell
2,407,347
-2,924,053
-55% -$12.8M ﹤0.01% 1110
2023
Q2 		$26.5M Sell
5,331,400
-998,904
-16% -$5.4M ﹤0.01% 860
2023
Q1 		$31.3M Buy
6,330,304
+388,507
+7% +$2.49M ﹤0.01% 810
2022
Q4 		$37.4M Buy
5,941,797
+34,481
+0.6% +$319K 0.01% 740
2022
Q3 		$63.8M Buy
5,907,316
+348,140
+6% +$4.73M 0.01% 586
2022
Q2 		$63.4M Buy
5,559,176
+1,292,441
+30% +$11.5M 0.01% 805
2022
Q1 		$38.9M Buy
4,266,735
+1,015,207
+31% +$10.6M ﹤0.01% 1055
2021
Q4 		$48.5M Sell
3,251,528
-1,087,463
-25% -$19.2M ﹤0.01% 1017
2021
Q3 		$112M Buy
4,338,991
+803,807
+23% +$19.1M 0.01% 731
2021
Q2 		$92.2M Buy
3,535,184
+78,431
+2% +$2.24M 0.01% 808
2021
Q1 		$122M Sell
3,456,753
-103,040
-3% -$3.48M 0.01% 711
2020
Q4 		$89.8M Sell
3,559,793
-17,891
-0.5% -$583K 0.01% 756
2020
Q3 		$135M Sell
3,577,684
-213,102
-6% -$8.03M 0.02% 582
2020
Q2 		$162M Buy
3,790,786
+1,586,252
+72% +$57.4M 0.02% 516
2020
Q1 		$42.9M Sell
2,204,534
-265,976
-11% -$6.34M 0.01% 831
2019
Q4 		$64.2M Sell
2,470,510
-48,162
-2% -$1.33M 0.01% 817
2019
Q3 		$68.6M Sell
2,518,672
-4,234
-0.2% -$121K 0.01% 746
2019
Q2 		$67.7M Buy
2,522,906
+3,398
+0.1% +$94.7K 0.01% 770
2019
Q1 		$70.9M Buy
2,519,508
+7,510
+0.3% +$218K 0.01% 738
2018
Q4 		$65.9M Buy
+2,511,998
New +$66.7M 0.01% 722

Other funds holding ALLO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

T. Rowe Price Associates's ALLO Position: Q2 2026 in Review

T. Rowe Price Associates reduced its Allogene Therapeutics (ALLO) stake by 14% in Q2 2026, selling an estimated $1.63M and leaving 4,639,283 shares worth $9.65M. The position accounts for ﹤0.01% of the portfolio, ranked #1341.

T. Rowe Price Associates first reported a position in ALLO in Q4 2018 and has held it in 31 quarters since. The position peaked at $162M in Q2 2020. 210 funds tracked by Wall St. Rank hold ALLO as of Q2 2026.

  • T. Rowe Price Associates held 4,639,283 shares of Allogene Therapeutics worth $9.65M as of Q2 2026.
  • T. Rowe Price Associates sold 741,619 Allogene Therapeutics shares in Q2 2026, an estimated $1.63M.
  • Allogene Therapeutics made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q2 2026, its #1341 holding.
  • T. Rowe Price Associates first reported a position in Allogene Therapeutics in Q4 2018 and has held it in 31 quarters since.
  • T. Rowe Price Associates's Allogene Therapeutics position peaked at $162M in Q2 2020.
  • 210 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q2 2026.

Based on T. Rowe Price Associates's 13F filing for Q2 2026, filed 14 Aug 2026.